Particle Health vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Particle Health provides a health data exchange API enabling healthcare apps to access longitudinal patient records from national networks with a single integration.
About
Particle Health is a health data exchange company founded in 2018 that provides developers and healthcare companies with a single API to access patient clinical records from national health information networks including CommonWell, Carequality, and others. The company abstracts the complexity of connecting to dozens of regional health information exchanges and national networks behind a simple developer-friendly API, enabling healthcare applications to retrieve longitudinal patient records including medical history, lab results, diagnoses, and medications from any participating provider. Particle raised $60M and serves digital health companies, telehealth platforms, health plans, and healthcare analytics firms that need access to real-world patient data to power clinical decision support, care management, and value-based care programs. The company provides HIPAA-compliant data access with identity verification and purpose-of-treatment validation to ensure appropriate use of patient records. Particle's API approach reduces the time and cost for healthcare companies to build clinical data infrastructure from months of complex integrations to days of API implementation.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.